AIA Review Of Wyeth's Tygacil Sought By Drug-Pricing Group
Wyeth LLC's patent for Tygacil, a drug based on the antibiotic tigecycline, on Friday entered the sights of a self-proclaimed patients' rights organization, which argued for inter partes review at the...To view the full article, register now.
Already a subscriber? Click here to view full article